See more : Jersey Oil and Gas Plc (JYOGF) Income Statement Analysis – Financial Results
Complete financial analysis of Tyme Technologies, Inc. (TYME) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Tyme Technologies, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Ling Yui Holdings Limited (0784.HK) Income Statement Analysis – Financial Results
- Infibeam Avenues Limited (INFIBEAM.NS) Income Statement Analysis – Financial Results
- PT Toba Pulp Lestari Tbk (INRU.JK) Income Statement Analysis – Financial Results
- Rajasthan Cylinders and Containers Ltd. (RCCL.BO) Income Statement Analysis – Financial Results
- China Railway Materials Company Limited (000927.SZ) Income Statement Analysis – Financial Results
Tyme Technologies, Inc. (TYME)
About Tyme Technologies, Inc.
Tyme Technologies, Inc., a biotechnology company, develops cancer metabolism-based therapies (CMBTs) in the United States. Its lead drug product is SM-88, a CMBT that is in a Phase II/III clinical trial to treat across 15 types of cancer, including pancreatic, prostate, breast, lung, glioma, ovarian, sarcoma, and colon. The company is also developing TYME-19, an oral synthetic member of the bile acid family, which is in preclinical stage for the treatment of SARS CoV-2 diseases; and TYME-18, a CMBT compound that is in preclinical stage for the treatment of inoperable tumors. It has research collaborations with Mayo Clinic to perform in-depth analysis of pancreatic cancer cell gene expression, epigenetic, and metabolism changes from SM-88 treatment; and a research investigator at Georgetown University to examine the effects of SM-88 in breast cancer. The company was formerly known as Global Group Enterprises Corp. The company was incorporated in 2011 and is headquartered in Bedminster, New Jersey. As of September 16, 2022, Tyme Technologies, Inc. operates as a subsidiary of Syros Pharmaceuticals, Inc.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 13.44M | 17.03M | 12.96M | 14.72M | 8.84M | 6.11M | 3.82M | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 9.63M | 10.19M | 12.80M | 14.59M | 10.52M | 9.10M | 4.78M | 53.91K | 56.59K | 27.43K | 2.10K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 9.63M | 10.19M | 12.80M | 14.59M | 10.52M | 9.10M | 4.78M | 53.91K | 56.59K | 27.43K | 2.10K |
| Other Expenses | 2.44M | 0.00 | 0.00 | 2.47M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.20K |
| Operating Expenses | 23.08M | 27.22M | 25.76M | 29.31M | 19.36M | 15.21M | 8.60M | 53.91K | 56.59K | 27.43K | -2.10K |
| Cost & Expenses | 23.08M | 27.22M | 25.76M | 29.31M | 19.36M | 15.21M | 8.60M | 53.91K | 56.59K | 27.43K | 2.10K |
| Interest Income | 0.00 | 22.08K | 229.46K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 70.24K | 97.13K | 114.24K | 0.00 | 0.00 | 0.00 | 3.50M | 76.56K | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 1.96M | 5.18K | 5.18K | 8.42K | 4.30K | 4.28K | 4.29K | 76.56K | 0.00 | 0.00 | 0.00 |
| EBITDA | -23.56M | -27.22M | -25.76M | -31.78M | -19.36B | -15.21B | -8.60M | 22.65K | -56.59K | -27.43K | -2.10K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -25.51M | -27.22M | -25.76M | -31.78M | -19.36M | -15.21M | -8.60M | -53.91K | -56.59K | -27.43K | -2.10K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.89M | -1.76M | 3.76M | -1.21M | 19.34B | 15.19B | -3.13M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -23.63M | -28.98M | -22.00M | -32.98M | -18.97M | -15.21M | -11.73M | -53.91K | -56.59K | -27.43K | -2.10K |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -1.96M | -1.66M | 3.87M | -1.21M | 390.39K | 0.00 | 376.26K | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -21.67M | -28.98M | -22.00M | -32.98M | -18.97M | -15.21M | -11.73M | -53.91K | -56.59K | -27.43K | -2.10K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.13 | -0.22 | -0.19 | -0.32 | -0.21 | -0.18 | -0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.13 | -0.22 | -0.19 | -0.32 | -0.21 | -0.18 | -0.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| Weighted Avg Shares Out | 172.21M | 134.25M | 114.53M | 102.35M | 90.57M | 84.45M | 77.85M | 52.00M | 12.00M | 47.60M | 39.00M |
| Weighted Avg Shares Out (Dil) | 172.21M | 134.25M | 114.53M | 102.35M | 90.57M | 84.45M | 77.85M | 52.00M | 12.00M | 47.60M | 39.00M |
Why Tyme Technologies Stock Is Crushing It Today
Why Tyme Technologies Shares Are Surging Higher
Revisiting Tyme Technologies
TYME Announces SM-88 Abstract Selected for Presentation at the American Society of Clinical Oncology 2021 Gastrointestinal Cancers Symposium
TYME Builds Leadership Team with Announcement of New CEO
Is Tyme Technologies, Inc. (TYME) Going to Burn These Hedge Funds?
Tyme Technologies: Killing Cancer By Compromising Tumor Cell Metabolism (NASDAQ:TYME)
Tyme Technologies to Webcast Conference Call of Fourth Quarter and Fiscal Year 2020 Financial and Operating Results on May 20, 2020
Source: https://incomestatements.info
Category: Stock Reports